JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 1998; 31:992-1001
© 1998 by the American College of Cardiology Foundation
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gregorini, L
Right arrow Articles by Zanchetti, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gregorini, L
Right arrow Articles by Zanchetti, A

Postischemic left ventricular dysfunction is abolished by alpha-adrenergic blocking agents

L Gregorini, J Marco, C Palombo, M Kozakova, GB Anguissola, B Cassagneau, M Bernies, A Distante, I Marco, J Fajadet, and A Zanchetti

Clinica Medica Generale, Ospedale Maggiore-IRCCS, University of Milano, Italy. gregorm@imiucca.csi.unimi.it

OBJECTIVES: We sought to evaluate the efficacy of alpha-adrenergic blocking agents in counteracting left ventricular (LV) dysfunction occurring after transient ischemia in humans. BACKGROUND: The mechanisms underlying postischemic LV dysfunction are largely unknown. METHODS: Percutaneous transluminal coronary angioplasty (PTCA) provides a clinical model of ischemia and reperfusion. In 50 patients undergoing coronary stenting for 77+/-5% stenosis, LV function was monitored by transesophageal echocardiography during and 30-min after PTCA. Fifteen minutes after stenting, 15 patients received 12 microg/kg body weight of the alpha-blocker phentolamine intracoronarily, 15 patients received 600 microg/kg of the alpha1-blocker urapidil intravenously, 10 patients received the combination of phentolamine and 1.2 mg of propranolol intracoronarily, and 10 patients received saline. RESULTS: Fifteen minutes after successful coronary dilation, significant contractile dysfunction occurred in previously ischemic and nonischemic myocardium. LV dysfunction was accompanied by an increase in coronary resistance and diffuse vasoconstriction. Alpha-blockers counteracted LV dysfunction and coronary resistance and the increase in vasoconstriction. Phentolamine and urapidil increased global LV shortening from 34+/-9% to 45+/-8% and to 49+/-8%, respectively (p < 0.05). After the administration of propranolol combined with phentolamine, LV dysfunction remained unchanged (34+/-6%), as in control subjects. CONCLUSIONS: LV dysfunction occurs after PTCA, as described in animal models after ischemia. Alpha-blockers abolished LV, macrocirculatory and microcirculatory dysfunction, whereas the alpha-blocker effect was prevented by combining alpha- and beta-blockers. The evidence of diffuse rather than regional dysfunction, together with the opposite effects of alpha- and beta-blockade, supports the hypothesis of neural mechanisms eliciting postischemic LV dysfunction.


This article has been cited by other articles:


Home page
NEJMHome page
P. G. Camici and F. Crea
Coronary Microvascular Dysfunction
N. Engl. J. Med., February 22, 2007; 356(8): 830 - 840.
[Full Text] [PDF]


Home page
Eur Heart JHome page
J. Herrmann
Peri-procedural myocardial injury: 2005 update
Eur. Heart J., December 1, 2005; 26(23): 2493 - 2519.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
E. Barbato, J. Bartunek, W. Aarnoudse, M. Vanderheyden, F. Staelens, W. Wijns, G. R. Heyndrickx, N. H.J. Pijls, and B. De Bruyne
Alpha-adrenergic receptor blockade and hyperaemic response in patients with intermediate coronary stenoses
Eur. Heart J., November 2, 2004; 25(22): 2034 - 2039.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
G. Heusch
Emerging importance of alpha-adrenergic coronary vasoconstriction in acute coronary syndromes and its genetic background
J. Am. Coll. Cardiol., January 15, 2003; 41(2): 195 - 196.
[Full Text] [PDF]


Home page
CirculationHome page
L. Gregorini, J. Marco, B. Farah, M. Bernies, C. Palombo, M. Kozakova, I. M. Bossi, B. Cassagneau, J. Fajadet, C. Di Mario, et al.
Effects of Selective {alpha}1- and {alpha}2-Adrenergic Blockade on Coronary Flow Reserve After Coronary Stenting
Circulation, December 3, 2002; 106(23): 2901 - 2907.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
G. Heusch, D. Baumgart, P. Camici, W. Chilian, L. Gregorini, O. Hess, C. Indolfi, and O. Rimoldi
{alpha}-Adrenergic Coronary Vasoconstriction and Myocardial Ischemia in Humans
Circulation, February 15, 2000; 101(6): 689 - 694.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. J. Kern
Appreciating {alpha}-Adrenergic Receptors and Their Role in Ischemic Left Ventricular Dysfunction
Circulation, February 2, 1999; 99(4): 468 - 471.
[Full Text] [PDF]


Home page
CirculationHome page
L. Gregorini, J. Marco, M. Kozakova, C. Palombo, G. B. Anguissola, I. Marco, M. Bernies, B. Cassagneau, A. Distante, I. M. Bossi, et al.
{alpha}-Adrenergic Blockade Improves Recovery of Myocardial Perfusion and Function After Coronary Stenting in Patients With Acute Myocardial Infarction
Circulation, February 2, 1999; 99(4): 482 - 490.
[Abstract] [Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1998 by the American College of Cardiology Foundation.